tradingkey.logo
搜尋

Harrow Inc

HROW
添加自選
38.450USD
-3.430-8.19%
收盤 07-24 16:00美東報價延遲15分鐘
1.43B總市值
虧損本益比TTM

關於 Harrow Inc 公司

Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

Harrow Inc簡介

公司代碼HROW
公司名稱Harrow Inc
上市日期Feb 08, 2013
CEOMullery (Frank)
員工數量382
證券類型Ordinary Share
年結日Feb 08
公司地址1A Burton Hills Blvd
城市NASHVILLE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編37215
電話16157334731
網址https://www.harrow.com/
公司代碼HROW
上市日期Feb 08, 2013
CEOMullery (Frank)

Harrow Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
814.68K
+0.43%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
19.80K
+5.05%
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
19.80K
+5.05%
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Mr. Amir Shojaei, Ph.D.
Mr. Amir Shojaei, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Randall E. Pollard, CPA
Mr. Randall E. Pollard, CPA
Chief Accounting Officer
Chief Accounting Officer
--
--
Mr. Frank Mullery
Mr. Frank Mullery
Chief Executive Officer of ImprimisRx
Chief Executive Officer of ImprimisRx
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
814.68K
+0.43%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
19.80K
+5.05%
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
19.80K
+5.05%
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Mr. Amir Shojaei, Ph.D.
Mr. Amir Shojaei, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--

常見問題

Harrow Inc的前五大股東是誰?

Harrow Inc的前五大股東如下:Mr. Mark L. Baum, J.D.

有多少機構持有Harrow Inc(HROW)的股份?

截至2026Q1,共有418家機構持有Harrow Inc的股份,合計持有的股份價值約為24.67M,占公司總股份的66.17% 。與2025Q4相比,機構持股有所增加,增幅為347374.00。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有